Paradigm Biopharmaceuticals
- Short interest
- 0.09%
- −0.01 pp 30d
- as of 8 Oct 2026
- Reported shorts
- 593.5K
- Shares on issue
- 626.433M
Paradigm Biopharmaceuticals (PAR) Short Interest
Paradigm Biopharmaceuticals (ASX:PAR) had 0.09% of shares reported as short positions as of 8 Oct 2026, representing 593,492 shares. Paradigm Biopharmaceuticals operates in the Pharmaceuticals, Biotechnology & Life Sciences industry. Source: ASIC short position report (T+4 delay).
Source: official ASIC short position report, T+4 delay. Methodology · Disclaimer — not financial advice.
Price & short interest
Toggle series, zoom, and compare · ASIC daily, T+4About Paradigm Biopharmaceuticals
Paradigm Biopharmaceuticals is a late-stage drug development company with the mission to develop and commercialise pentosan polysulfate sodium for the treatment of pain associated with musculoskeletal disorders driven by injury, inflammation, ageing, dege
Company profile →Paradigm Biopharmaceuticals (ASX:PAR) has 0.09% of its shares on issue reported as short positions as of 8 Oct 2026, or about 593,492 shares. Over the past 30 days that figure has been broadly flat, and over 90 days it has risen 0.09 percentage points. Its highest recorded short interest was 4.77% in March 2022. PAR is classified in the Pharmaceuticals, Biotechnology & Life Sciences industry. All figures come from official ASIC short position reports, published with a four trading-day (T+4) delay.
Short interest
History & FAQ →Weekly context: The 10 most shorted ASX stocks — Week 41, 2026.
Strategy fit
How each stock picker strategy reads PAR today
- Zanger BreakoutWatchScore 10rank 1664 of 1942
- CAN SLIMWatchScore 15rank 945 of 1541
- Minervini Trend TemplateWatchScore 27rank 637 of 1716
- Crowded-Short BreakoutWatchScore 15rank 656 of 1502
- Quality compoundersWatchScore 26rank 497 of 1669
Prices to 14 Oct 2026 · Mechanical readings of published rules, not recommendations · Not financial adviceFull strategy readings →
PAR fundamentals
In the year to 30 Jun 2026, Paradigm Biopharmaceuticals (ASX:PAR) recorded revenue of A$80.2K and a net loss after tax of A$56.3M. Net margin −70,282.3% (FY). Figures are in AUD, the company's reporting currency; source: Yahoo Finance, as at 1 Oct 2026.
Full statements, ratios and filings are on the Financials tab. Not financial advice.
Latest PAR news
All news- Expiry of PAROB Listed Options
asx · 11 Oct 2026
- Notification of cessation of securities - PAR
asx · 7 Oct 2026
- Update on Data Review and Convertible note redemption
asx · 7 Oct 2026
Company details
website
address
More Pharmaceuticals, Biotechnology & Life Sciences Stocks
Other shorted stocks in this sector
Be the first to discuss PAR
Start a research thread or post the first pulse update